27.08
0.05 (0.18%)
| Penutupan Terdahulu | 27.03 |
| Buka | 26.83 |
| Jumlah Dagangan | 772,818 |
| Purata Dagangan (3B) | 1,330,076 |
| Modal Pasaran | 1,215,954,432 |
| Harga / Pendapatan (P/E TTM) | 3.53 |
| Harga / Buku (P/B) | 3.84 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| EPS Cair (TTM) | -2.20 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.05% |
| Nisbah Semasa (MRQ) | 23.31 |
| Aliran Tunai Operasi (OCF TTM) | -66.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -42.10 M |
| Pulangan Atas Aset (ROA TTM) | -31.68% |
| Pulangan Atas Ekuiti (ROE TTM) | -48.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | MBX Biosciences, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.13 |
|
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 3.12% |
| % Dimiliki oleh Institusi | 106.60% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 80.00 (Oppenheimer, 195.42%) | Beli |
| Median | 56.00 (106.80%) | |
| Rendah | 18.00 (Goldman Sachs, -33.53%) | Jual |
| Purata | 56.20 (107.53%) | |
| Jumlah | 4 Beli, 1 Jual | |
| Harga Purata @ Panggilan | 21.61 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Goldman Sachs | 04 Dec 2025 | 18.00 (-33.53%) | Jual | 30.54 |
| Guggenheim | 10 Nov 2025 | 77.00 (184.34%) | Beli | 24.49 |
| 23 Sep 2025 | 84.00 (210.19%) | Beli | 18.96 | |
| Truist Securities | 15 Oct 2025 | 50.00 (84.64%) | Beli | 13.95 |
| Mizuho | 24 Sep 2025 | 56.00 (106.79%) | Beli | 20.10 |
| Oppenheimer | 23 Sep 2025 | 80.00 (195.42%) | Beli | 18.96 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Nov 2025 | Pengumuman | MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference |
| 06 Nov 2025 | Pengumuman | MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights |
| 20 Oct 2025 | Pengumuman | MBX Biosciences to Participate in November Investor Conferences |
| 29 Sep 2025 | Pengumuman | MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum |
| 24 Sep 2025 | Pengumuman | MBX Biosciences Announces Pricing of Upsized Public Offering |
| 22 Sep 2025 | Pengumuman | MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension |
| 22 Sep 2025 | Pengumuman | MBX Biosciences Announces Proposed Public Offering |
| 19 Sep 2025 | Pengumuman | MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |